InvestorsHub Logo
Followers 36
Posts 2689
Boards Moderated 0
Alias Born 06/09/2011

Re: None

Thursday, 03/26/2020 2:09:24 PM

Thursday, March 26, 2020 2:09:24 PM

Post# of 16750
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
GlobeNewswire GlobeNewswire•March 26, 2020
Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population

Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage III/IV Ovarian Cancer


https://finance.yahoo.com/news/celsion-ovation-1-study-gen-120010020.html